Spondyloarthritis & psoriatic arthritis
Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina
Authors' conclusion
The delay in receiving SEC was longer in patients with public health insurance. Patients using SEC as third-line or higher therapy had 3.4 times less survival. AEs were mild and no AEs of interest were observed.
Study context
- Population
- Patients ≥18 years with axial spondyloarthritis (axSpA) or axial psoriatic arthritis (axPsA) who had received ≥1 dose of secukinumab, Argentina
- Participants
- 117 patients
- Exposure
- Secukinumab in axPsA vs axSpA
- axPsAn = 72
- axSpAn = 45reference
- Outcome
- Effectiveness: Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) <4
- Follow-up
- 6 months
Methodological detailsmulticentre, observational, real-world
- Multicentre
- Observational
- Real-world
Main finding
As reported in the abstract
Effectiveness of SEC (BASDAI <4)
P = 0.91
- Effectiveness, all patients
- 72/117 (61.5%)
Observational data: associations, not effects.
Further findings
Factor associated with reduced secukinumab (SEC) survival: SEC as third-line treatment or higher
| HR for reduced SEC survival (drug discontinuation) (95% CI) | P value | ||
|---|---|---|---|
| SEC as third-line or higherOnly factor associated with reduced survival; Cox regression | 3.43 (1.11–11.10) | P = 0.04 | |
| 0.050.21520HR for reduced SEC survival (drug discontinuation) (log scale) |
| Outcome | Values | P value |
|---|---|---|
| Delay in receiving SEC (days from request to first application)Public health insurance vs Social security system · longer delay with public health insurance | Public health insurance median 90 (IQR 60–150) days | P = 0.01 |
| Delay in receiving SEC (days from request to first application)Public health insurance vs Private health coverage · longer delay with public health insurance | P = 0.009 |
SEC drug survival
- Median SEC survival
- 48 months (95% CI 32-63)
- Kaplan-Meier
Safety
Incidence of adverse events (AEs)
- AEs, events/100 patients/year
- 7.9 (95% CI 5-12)
- AEs were mild and no AEs of interest were observed
Original publication
Access, Effectiveness, Safety, and Survival of Secukinumab in Patients With Axial Spondyloarthritis and Axial Psoriatic Arthritis: A Real-World Study in Argentina. J Rheumatol. Published 15 May 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →